|Common names||Allylescaline, AL|
|Routes of Administration|
|Summary sheet: Allylescaline|
4-Allyloxy-3,5-dimethoxyphenethylamine (also known as allylescaline) is a lesser-known novel psychedelic substance of the phenethylamine class. It is a structural analog of mescaline and related to escaline and methallylescaline. It is relatively uncommon and has little to no history of human usage.
The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 20 – 35 mg orally and describes the duration of action to be 8 - 12 hours.
Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline. It is highly advised to use harm reduction practices if using this substance.
Allylescaline, or 4-allyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. Escaline contains two methoxy functional groups CH3O- which are attached to carbons R3, and R5 and an additional allyloxy group at carbon R4 of the phenyl ring. Allylescaline is the 4-allyloxy analog of mescaline.
Allylescaline, also referred to as 4-allyloxy-3,5-dimethoxyphenethylamine, is research compounds that is not well-known. The IUPAC name for Allylescaline is 4-Allyloxy-3,5-dimethoxyphenethylamine 4-Allyloxy-3,5-dimethoxy-1-ethylami with the molecular formula being C13H19NO3 and a molecular weight of 237.29 g/mol. Allylescaline is known to have an average mass of 237.294998 Da and a monoisotopic mass of 237.136002 Da.
Allylescaline acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from allylescaline's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
It is the 4O-allyl homolog of mescaline, and binds similarly to the serotonin receptors. It seems to have considerably increased potency by weight, with an active dose in humans reported to be 20-40 mg (compared to 300-400 mg for mescaline).
It is relatively uncommon and has little to no history of human usage. Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline. The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational allylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because allylescaline is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried allylescaline suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Allylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of allylescaline is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Allylescaline presents cross-tolerance with all psychedelics, meaning that after the consumption of allylescaline all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: Allylescaline is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of February 1, 1997 (called "4-Allyloxy-3,5-dimethoxy-phenethylazan"). It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Sweden: Allylescaline is illegal in Sweden as of January 2016.
- Switzerland: Allylescaline is a controlled substance specifically named under Verzeichnis E.
- United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- Shulgin, Alexander; Shulgin, Ann (1991). "#2. AL". PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264.
- "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Neunte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 1997 Teil I Nr. 5 (in German). Bundesanzeiger Verlag (published January 31, 1997). January 28, 1997. p. 65. ISSN 0341-1095.
- "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "31 nya ämnen kan klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Psychoactive Substances Act 2016". UK Government. Retrieved January 1, 2020.